A Phase 3 interventional study of Fluticasone furoate and Placebo in Rhinitis, Allergic, Perennial, sponsored by GlaxoSmithKline. Completed at 22 sites in Japan. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2017-01-11.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing fluticasone furoate in Rhinitis, Allergic, Perennial — none open to participants now, none under way, none of them phase 3. fluticasone furoate · Rhinitis, Allergic, Perennial.
Among the 15 studies testing fluticasone furoate in Rhinitis, Allergic, Perennial, this one is the 9th largest by enrollment, is the only one that started in 2012, is one of 11 in phase 3, and was the 15th registered.
178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.
Browse Rhinitis, Allergic, Perennial studies →None of the 15 studies testing fluticasone furoate in Rhinitis, Allergic, Perennial is open now. The open studies under Rhinitis, Allergic, Perennial, anywhere →
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 6 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 261 is above the median of 135 across 157 interventional studies indexed under Rhinitis, Allergic, Perennial.
Median enrollment 288 across the 15 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 1 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
28 studies in Rhinitis, Allergic, Perennial by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 28 finished, 13 (46%) have results posted.
Among the 28 studies in Rhinitis, Allergic, Perennial by GlaxoSmithKline, this one is the 12th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2012, is one of 16 in phase 3, and was the 28th registered.
GlaxoSmithKline’s Rhinitis, Allergic, Perennial studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing fluticasone furoate in Rhinitis, Allergic, Perennial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 28 in Rhinitis, Allergic, Perennial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Efficacy and safety of GW685698X (55 µg/day, q.d.) nasal spray over a period of 2 weeks in Japanese paediatric subjects ages 6 to \< 15 years with perennial allergic rhinitis will be evaluated compared with placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Anti-IgE (Within 6 months prior to Visit 1), medications or Systemic corticosteroids (Within 8 weeks prior to Visit 1), Topical corticosteroids (Within 4 weeks prior to Visit 1), Immunotherapy or nonspecific allassotherapy which was initiated, discontinued or changed its dose within 4 weeks prior to Visit 1
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GW685698X 55mcg/day
Drug: Fluticasone furoate
Placebo
Drug: Placebo
55 mcg/day, intranasal, 2 weeks
Placebo, intranasal, 2 weeks
Mean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the mean score for the entire treatment period minus the score at Baseline.
Time frame: Baseline through the entire treatment period (2 weeks)
Mean Change From Baseline in 3TNSS at Week 1 and Week 2
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For Week 1 and Week 2, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the mean score at Week 1 and Week 2 minus the score at Baseline.
Time frame: Baseline; Week 1 and Week 2
Mean Percent Change From Baseline in 3TNSS Over the Entire Treatment Period, at Week 1, and at Week 2
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire treatment period (Weeks 1 and 2), Week 1, and Week 2, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.
Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Mean Change From Baseline in 3TNSS at the Indicated Days
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). Change from Baseline was calculated as the mean score at the indicated day minus the score at Baseline.
Time frame: Baseline; Days 1 through 14
Mean Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, at Week 1, and at Week 2
The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the 4TNSS in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Mean Percent Change From Baseline in the 4TNSS Over the Entire Treatment Period, at Week 1, and at Week 2
The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 4TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire treatment period (Weeks 1 and 2), Week 1, and Week 2, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.
Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Mean Change From Baseline in Rhinorrhea, Nasal Congestion, Sneezing, and Nasal Itching Over the Entire Treatment Period (ETP), at Week 1, and at Week 2
Four individual symptoms (sneezing, rhinorrhea, nasal congestion, and nasal itching) were scored on a scale from 0 to 3 using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the symptom scores in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Mean Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, at Week 1, and at Week 2
Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Mean Change From Baseline (BL) in the Total Ocular Symptom Score (TOSS) for the Baseline TOSS >0 Over the Entire Treatment Period, at Week 1, and at Week 2
Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Mean Percent Change From Baseline (BL) in the TOSS Over the Entire Treatment Period, at Week 1, and at Week 2
Symptoms of eye itching, tearing, and redness were scored by the participant's (par.) parent/guardian who signed the ICF or the par. themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the par.'s diary. The TOSS is the sum of all 3 symptom scores and ranges from 0 to 9. The mean of the BL period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each par. was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from BL=(mean score at post-BL assessment minus score at BL) divided by the BL value \* 100. Par. with a BL TOSS of 0 were not analyzed because percent change from BL could not be calculated.
Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Mean Percent Change From Baseline (BL) in the TOSS for the Baseline TOSS >0 Over the Entire Treatment Period, at Week 1, and at Week 2
Symptoms of eye itching, tearing, and redness were scored by the participant's (par.) parent/guardian who signed the ICF or the par. themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the par.'s diary. The TOSS is the sum of all 3 symptom scores and ranges from 0 to 9. The mean of the BL period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each par. was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from BL=(mean score at post-BL assessment minus score at BL) divided by the BL value \* 100.
Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Mean Change From Baseline in the Individual Ocular Symptom Scores (Eye Itching, Tearing, and Redness) Over the Entire Treatment Period, at Week 1, and at Week 2
Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Mean Change From Baseline in the Score of Troubles With Daily Life Over the Entire Treatment Period, at Week 1, and at Week 2
The participant's parent/guardian who signed the ICF or the participant themself scored the participant's troubles with daily life once daily using the following scale: 0, None; 1, Few troubles; 2, Intermediate between 3 and 1; or 3, Painful and complicating daily life. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Number of Participants With the Indicated Scores for Rhinoscopy Findings (Swelling of Inferior Turbinate Mucosa, Color of Inferior Turbinate Mucosa, Quantity of Nasal Discharge, and Quality of Nasal Discharge) at Baseline, Week 1, and Week 2/EW
Rhinoscopy was assessed by the investigator by scoring swelling of inferior turbinate mucosa (SOITM) scored as 0 (none), 1 (possible to see center of the middle turbinate), 2 (between 3 and 1), or 3 (impossible to see middle turbinate); color of inferior turbinate mucosa (COITM) scored as 0 (normal), 1 (pink), 2 (red), or 3 (pale); quantity of nasal discharge (QTND) scored as 0 (none), 1 (small amount adhered), 2 (between 3 and 1), or 3 (filled); and quality of nasal discharge (QLND) scored as 0 (none), 1 (pyoid), 2 (viscous), or 3 (watery).
Time frame: Baseline, Week 1, and Week 2/Early Withdrawal (EW)
Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Investigator
The investigator evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.
Time frame: Week 2/EW
Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Participant's Parent/Guardian or the Participant
The participant's parent/guardian who signed the ICF or the participant themself evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.
Time frame: Week 2/EW
| Milestone | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Started | 131 | 130 |
| Completed | 131 | 128 |
| Not completed | 0 | 2 |
| Withdrew: Protocol-defined stopping criteria met | 0 | 2 |
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the mean score for the entire treatment period minus the score at Baseline.
| Scores on a scale | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Mean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period | -1.98 ± 0.12 | -0.89 ± 0.12 |
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For Week 1 and Week 2, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the mean score at Week 1 and Week 2 minus the score at Baseline.
| Scores on a scale | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Week 1, n=131, 130 | -1.60 ± 0.12 | -0.70 ± 0.12 |
| Week 2, n=131, 128 | -2.38 ± 0.13 | -1.10 ± 0.13 |
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire treatment period (Weeks 1 and 2), Week 1, and Week 2, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.
| Percent change | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Entire treatment period, n=131, 130 | -39.76 ± 2.38 | -17.74 ± 2.36 |
| Week 1, n=131, 130 | -31.96 ± 2.46 | -13.89 ± 2.44 |
| Week 2, n=131, 128 | -47.89 ± 2.70 | -21.95 ± 2.70 |
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). Change from Baseline was calculated as the mean score at the indicated day minus the score at Baseline.
| Scores on a scale | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Day 1, n=130, 130 | -0.71 ± 0.13 | -0.52 ± 0.12 |
| Day 2, n=131, 130 | -1.33 ± 0.14 | -0.41 ± 0.14 |
| Day 3, n=131, 130 | -1.53 ± 0.15 | -0.61 ± 0.15 |
| Day 4, n=131, 130 | -1.69 ± 0.15 | -0.77 ± 0.15 |
| Day 5, n=131, 130 | -1.89 ± 0.16 | -0.77 ± 0.16 |
| Day 6, n=131, 130 | -1.95 ± 0.16 | -0.97 ± 0.16 |
| Day 7, n=131, 130 | -2.05 ± 0.16 | -0.87 ± 0.16 |
| Day 8, n=131, 128 | -2.14 ± 0.16 | -1.05 ± 0.16 |
| Day 9, n=131, 128 | -2.29 ± 0.16 | -1.07 ± 0.16 |
| Day 10, n=131, 128 | -2.32 ± 0.16 | -1.01 ± 0.16 |
| Day 11, n=131, 128 | -2.36 ± 0.16 | -1.19 ± 0.16 |
| Day 12, n=131, 128 | -2.54 ± 0.15 | -1.21 ± 0.15 |
| Day 13, n=122, 123 | -2.47 ± 0.16 | -1.20 ± 0.16 |
| Day 14, n=105, 115 | -2.65 ± 0.17 | -0.93 ± 0.16 |
The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the 4TNSS in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Scores on a scale | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Entire Treatment Period, n=131, 130 | -2.40 ± 0.15 | -1.01 ± 0.15 |
| Week 1, n=131, 130 | -1.94 ± 0.15 | -0.74 ± 0.15 |
| Week 2, n= 131, 128 | -2.89 ± 0.16 | -1.29 ± 0.16 |
The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 4TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire treatment period (Weeks 1 and 2), Week 1, and Week 2, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.
| Percent change | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Entire Treatment Period, n=131, 130 | -40.42 ± 2.46 | -16.09 ± 2.44 |
| Week 1, n=131, 130 | -32.55 ± 2.54 | -11.54 ± 2.52 |
| Week 2, n= 131, 128 | -48.58 ± 2.78 | -20.92 ± 2.78 |
Four individual symptoms (sneezing, rhinorrhea, nasal congestion, and nasal itching) were scored on a scale from 0 to 3 using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the symptom scores in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Scores on a scale | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Rhinorrhea, ETP, n=131, 130 | -0.69 ± 0.05 | -0.31 ± 0.05 |
| Rhinorrhea, Week 1, n=131, 130 | -0.55 ± 0.05 | -0.23 ± 0.05 |
| Rhinorrhea, Week 2, n=131, 128 | -0.85 ± 0.06 | -0.40 ± 0.06 |
| Nasal congestion, ETP, n=131, 130 | -0.70 ± 0.05 | -0.36 ± 0.05 |
| Nasal congestion, Week 1, n=131, 130 | -0.56 ± 0.05 | -0.29 ± 0.05 |
| Nasal congestion, Week 2, n=131, 128 | -0.84 ± 0.05 | -0.43 ± 0.05 |
| Sneezing, ETP, n=131, 130 | -0.60 ± 0.04 | -0.21 ± 0.04 |
| Sneezing, Week 1, n=131, 130 | -0.50 ± 0.04 | -0.16 ± 0.04 |
| Sneezing, Week 2, n= 131, 128 | -0.71 ± 0.05 | -0.27 ± 0.05 |
| Nasal itching, ETP, n=131, 130 | -0.41 ± 0.04 | -0.12 ± 0.04 |
| Nasal itching, Week 1, n=131, 130 | -0.33 ± 0.05 | -0.04 ± 0.05 |
| Nasal itching, Week 2, n= 131, 128 | -0.49 ± 0.05 | -0.19 ± 0.05 |
Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Scores on a scale | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Entire Treatment Period, n=131, 130 | -0.46 ± 0.09 | -0.32 ± 0.09 |
| Week 1, n=131, 130 | -0.31 ± 0.09 | -0.22 ± 0.09 |
| Week 2, n= 131, 128 | -0.61 ± 0.10 | -0.39 ± 0.10 |
Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Scores on a scale | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Entire Treatment Period, n=99, 92 | -0.77 ± 0.11 | -0.47 ± 0.11 |
| Week 1, n=99, 92 | -0.56 ± 0.11 | -0.35 ± 0.11 |
| Week 2, n= 99, 90 | -0.99 ± 0.13 | -0.56 ± 0.13 |
Symptoms of eye itching, tearing, and redness were scored by the participant's (par.) parent/guardian who signed the ICF or the par. themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the par.'s diary. The TOSS is the sum of all 3 symptom scores and ranges from 0 to 9. The mean of the BL period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each par. was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from BL=(mean score at post-BL assessment minus score at BL) divided by the BL value \* 100. Par. with a BL TOSS of 0 were not analyzed because percent change from BL could not be calculated.
| Percent change | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Entire Treatment Period, n=99, 92 | -20.97 ± 11.39 | 1.57 ± 11.64 |
| Week 1, n=99, 92 | -9.20 ± 10.90 | 5.37 ± 11.14 |
| Week 2, n= 99, 90 | -33.52 ± 13.27 | -1.70 ± 13.69 |
Symptoms of eye itching, tearing, and redness were scored by the participant's (par.) parent/guardian who signed the ICF or the par. themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the par.'s diary. The TOSS is the sum of all 3 symptom scores and ranges from 0 to 9. The mean of the BL period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each par. was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from BL=(mean score at post-BL assessment minus score at BL) divided by the BL value \* 100.
| Percent change | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Entire Treatment Period, n=99, 92 | -20.97 ± 11.39 | 1.57 ± 11.64 |
| Week 1, n=99, 92 | -9.20 ± 10.90 | 5.37 ± 11.14 |
| Week 2, n=99, 90 | -33.52 ± 13.27 | -1.70 ± 13.69 |
Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Scores on a scale | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Eye itching, Entire Treatment Period, n=131, 130 | -0.24 ± 0.04 | -0.18 ± 0.04 |
| Eye itching, Week 1, n=131, 130 | -0.15 ± 0.04 | -0.13 ± 0.04 |
| Eye itching Week 2, n=131, 128 | -0.34 ± 0.05 | -0.23 ± 0.05 |
| Tearing, Entire Treatment Period, n=131, 130 | -0.10 ± 0.03 | -0.05 ± 0.03 |
| Tearing, Week 1, n=131, 130 | -0.09 ± 0.03 | -0.03 ± 0.03 |
| Tearing, Week 2, n=131, 128 | -0.11 ± 0.03 | -0.07 ± 0.03 |
| Redness, Entire Treatment Period, n=131, 130 | -0.11 ± 0.03 | -0.09 ± 0.03 |
| Redness, Week 1, n=131, 130 | -0.07 ± 0.03 | -0.07 ± 0.03 |
| Redness, Week 2, n=130, 128 | -0.16 ± 0.04 | -0.10 ± 0.04 |
The participant's parent/guardian who signed the ICF or the participant themself scored the participant's troubles with daily life once daily using the following scale: 0, None; 1, Few troubles; 2, Intermediate between 3 and 1; or 3, Painful and complicating daily life. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Scores on a scale | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Entire Treatment Period, n=131, 130 | -0.43 ± 0.04 | -0.13 ± 0.04 |
| Week 1, n=131, 130 | -0.33 ± 0.04 | -0.10 ± 0.04 |
| Week 2, n=131, 128 | -0.53 ± 0.05 | -0.16 ± 0.05 |
Rhinoscopy was assessed by the investigator by scoring swelling of inferior turbinate mucosa (SOITM) scored as 0 (none), 1 (possible to see center of the middle turbinate), 2 (between 3 and 1), or 3 (impossible to see middle turbinate); color of inferior turbinate mucosa (COITM) scored as 0 (normal), 1 (pink), 2 (red), or 3 (pale); quantity of nasal discharge (QTND) scored as 0 (none), 1 (small amount adhered), 2 (between 3 and 1), or 3 (filled); and quality of nasal discharge (QLND) scored as 0 (none), 1 (pyoid), 2 (viscous), or 3 (watery).
| participants | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| SOITM, Baseline, Score 0, n=131, 130 | 2 | 7 |
| SOITM, Baseline, Score 1, n=131, 130 | 24 | 32 |
| SOITM, Baseline, Score 2, n=131, 130 | 54 | 55 |
| SOITM, Baseline, Score 3, n=131, 130 | 51 | 36 |
| SOITM, Week 1, Score 0, n=131, 128 | 9 | 5 |
| SOITM, Week 1, Score 1, n=131, 128 | 45 | 55 |
| SOITM, Week 1, Score 2, n=131, 128 | 53 | 44 |
| SOITM, Week 1, Score 3, n=131, 128 | 24 | 24 |
| SOITM, Week 2/EW, Score 0, n=131, 130 | 19 | 19 |
| SOITM, Week 2/EW, Score 1, n=131, 130 | 62 | 45 |
| SOITM, Week 2/EW, Score 2, n=131, 130 | 37 | 42 |
| SOITM, Week 2/EW, Score 3, n=131, 130 | 13 | 24 |
| COITM, Baseline, Score 0, n=131, 130 | 2 | 2 |
| COITM, Baseline, Score 1, n=131, 130 | 13 | 31 |
| COITM, Baseline, Score 2, n=131, 130 | 28 | 29 |
| COITM, Baseline, Score 3, n=131, 130 | 88 | 68 |
| COITM, Week 1, Score 0, n= 131, 128 | 5 | 2 |
| COITM, Week 1, Score 1, n= 131, 128 | 45 | 43 |
| COITM, Week 1, Score 2, n= 131, 128 | 23 | 27 |
| COITM, Week 1, Score 3, n= 131, 128 | 58 | 56 |
| COITM, Week 2/EW, Score 0, n=131, 130 | 7 | 10 |
| COITM, Week 2/EW, Score 1, n=131, 130 | 68 | 51 |
| COITM, Week 2/EW, Score 2, n=131, 130 | 17 | 20 |
| COITM, Week 2/EW, Score 3, n=131, 130 | 39 | 49 |
| QTND, Baseline, Score 0, n=131, 130 | 8 | 6 |
| QTND, Baseline, Score 1, n=131, 130 | 52 | 53 |
| QTND, Baseline, Score 2, n=131, 130 | 60 | 63 |
| QTND, Baseline, Score 3, n=131, 130 | 11 | 8 |
| QTND, Week 1, Score 0, n= 131, 128 | 38 | 18 |
| QTND, Week 1, Score 1, n= 131, 128 | 57 | 62 |
| QTND, Week 1, Score 2, n= 131, 128 | 32 | 42 |
| QTND, Week 1, Score 3, n= 131, 128 | 4 | 6 |
| QTND, Week 2/EW, Score 0, n=131, 130 | 63 | 37 |
| QTND, Week 2/EW, Score 1, n=131, 130 | 49 | 57 |
| QTND, Week 2/EW, Score 2, n=131, 130 | 18 | 31 |
| QTND, Week 2/EW, Score 3, n=131, 130 | 1 | 5 |
| QLND, Baseline, Score 0, n=131, 130 | 9 | 6 |
| QLND, Baseline, Score 1, n=131, 130 | 0 | 0 |
| QLND, Baseline, Score 2, n=131, 130 | 29 | 27 |
| QLND, Baseline, Score 3, n=131, 130 | 93 | 97 |
| QLND, Week 1, Score 0, n= 131, 128 | 39 | 18 |
| QLND, Week 1, Score 1, n= 131, 128 | 2 | 5 |
| QLND, Week 1, Score 2, n= 131, 128 | 24 | 27 |
| QLND, Week 1, Score 3, n= 131, 128 | 66 | 78 |
| QLND, Week 2/EW, Score 0, n=131, 130 | 62 | 33 |
| QLND, Week 2/EW, Score 1, n=131, 130 | 3 | 3 |
| QLND, Week 2/EW, Score 2, n=131, 130 | 26 | 29 |
| QLND, Week 2/EW, Score 3, n=131, 130 | 40 | 65 |
The investigator evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.
| participants | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Significantly improved | 32 | 12 |
| Moderately improved | 38 | 25 |
| Mildly improved | 36 | 31 |
| No change | 22 | 54 |
| Mildly worse | 1 | 5 |
| Moderately worse | 2 | 2 |
| Significantly worse | 0 | 1 |
The participant's parent/guardian who signed the ICF or the participant themself evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.
| participants | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| Significantly improved | 28 | 2 |
| Moderately improved | 51 | 26 |
| Mildly improved | 34 | 48 |
| No change | 18 | 51 |
| Mildly worse | 0 | 3 |
| Moderately worse | 0 | 0 |
| Significantly worse | 0 | 0 |
Collected over Participants were analyzed from the start of study treatment until the follow up contact (up to 3 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fluticasone Furoate 55 µg Per Day | — | 0/131 (0%) | 23/131 (17.6%) |
| Placebo | — | 0/130 (0%) | 25/130 (19.2%) |
| Event | Fluticasone Furoate 55 µg Per Day | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 6/131 | 3/130 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/131 | 3/130 |
| Alanine aminotransferase increasedInvestigations | 0/131 | 2/130 |
| Aspartate aminotransferase increasedInvestigations | 0/131 | 2/130 |
| HeadacheNervous system disorders | 0/131 | 2/130 |
| Conjunctivitis allergicEye disorders | 2/131 | 0/130 |
| BronchitisInfections and infestations | 1/131 | 1/130 |
| Otitis media acuteInfections and infestations | 0/131 | 1/130 |
| Pneumonia mycoplasmalInfections and infestations | 0/131 | 1/130 |
| Nasal discomfortRespiratory, thoracic and mediastinal disorders | 1/131 | 1/130 |
| Age, Continuous(Years) | Fluticasone Furoate 55 µg Per Day | Placebo | Total |
|---|---|---|---|
| Mean | 10.0 ± 2.32 | 10.1 ± 2.22 | 10.1 ± 2.26 |
| Gender(Participants) | Fluticasone Furoate 55 µg Per Day | Placebo | Total |
|---|---|---|---|
| Female | 46 | 51 | 97 |
| Male | 85 | 79 | 164 |
| Race/Ethnicity, Customized(participants) | Fluticasone Furoate 55 µg Per Day | Placebo | Total |
|---|---|---|---|
| Asian - Japanese Heritage | 131 | 130 | 261 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jun 2012, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone furoate
Rhinitis, Allergic, Perennial →